Published in JAMA on February 10, 2015
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol (2015) 2.18
Beyond muscles: The untapped potential of creatine. Int Immunopharmacol (2016) 0.83
Sex Differences in Clinical Features of Early, Treated Parkinson's Disease. PLoS One (2015) 0.82
Decade in review-movement disorders: Tracking the pathogenesis of movement disorders. Nat Rev Neurol (2015) 0.80
Time to change the blind men and the elephant approach to Parkinson disease? Neurology (2015) 0.79
Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine. Clin Neuropharmacol (2015) 0.79
Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease. FEBS Lett (2015) 0.78
Precision medicine for disease modification in Parkinson disease. Nat Rev Neurol (2017) 0.78
Therapeutic approaches in Parkinson's disease and related disorders. J Neurochem (2016) 0.78
Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease. Curr Neuropharmacol (2016) 0.77
Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study. J Dual Diagn (2015) 0.76
Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options. P T (2015) 0.75
Recent Publications by Ochsner Authors. Ochsner J (2015) 0.75
Anti-Oxidants in Parkinson's Disease Therapy: A Critical Point of View. Curr Neuropharmacol (2016) 0.75
Caffeine, creatine, GRIN2A and Parkinson's disease progression. J Neurol Sci (2017) 0.75
Bayesian multivariate augmented Beta rectangular regression models for patient-reported outcomes and survival data. Stat Methods Med Res (2015) 0.75
Two hundred steps. Nature (2016) 0.75
Augmented Beta rectangular regression models: A Bayesian perspective. Biom J (2015) 0.75
Autonomic and electrocardiographic findings in Parkinson's disease. Auton Neurosci (2017) 0.75
Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism. Brain Res Bull (2017) 0.75
A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease. PLoS One (2017) 0.75
A predictive model to identify Parkinson disease from administrative claims data. Neurology (2017) 0.75
Targeting urate to reduce oxidative stress in Parkinson disease. Exp Neurol (2017) 0.75
Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. J Neurol Sci (2017) 0.75
Predictors of weight loss in early treated Parkinson's disease from the NET-PD LS-1 cohort. J Neurol (2017) 0.75
EuroQol--a new facility for the measurement of health-related quality of life. Health Policy (1990) 59.70
Interobserver agreement for the assessment of handicap in stroke patients. Stroke (1988) 20.14
Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess (1996) 16.96
Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord (2010) 9.34
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology (2006) 6.86
Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem (1990) 4.03
Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol (1989) 3.11
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology (2006) 3.01
A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology (2007) 2.32
The B-value: a tool for monitoring data. Biometrics (1988) 2.08
Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology (2003) 2.04
The current and projected economic burden of Parkinson's disease in the United States. Mov Disord (2013) 1.80
Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology (2006) 1.69
Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord (2012) 1.49
Adjusting O'Brien's test to control type I error for the generalized nonparametric Behrens-Fisher problem. Biometrics (2005) 1.47
Assessment of cognition in Parkinson's disease. Neurology (2003) 1.45
Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann Neurol (1992) 1.45
Quality of life and Parkinson's disease: translation and validation of the US Parkinson's Disease Questionnaire (PDQ-39). Qual Life Res (1999) 1.39
Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol (1999) 1.37
A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol (2008) 1.13
Cross-cultural evaluation of the Parkinson's Disease Questionnaire: tests of data quality, score reliability, response rate, and scaling assumptions in the United States, Canada, Japan, Italy, and Spain. J Clin Epidemiol (2003) 0.99
Using global statistical tests in long-term Parkinson's disease clinical trials. Mov Disord (2009) 0.98
Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J Mol Neurosci (2003) 0.92
Bayesian multiple imputation for missing multivariate longitudinal data from a Parkinson's disease clinical trial. Stat Methods Med Res (2012) 0.89